Uterus DiseaseMIN-HYSTERNCT05102032
Impact of a Minimally Invasive Approach to Laparoscopic Hysterectomy on Postoperative Recovery
A study testing mini invasive approach and Conventional approach in people with Uterus Disease, run by Institut Mutualiste Montsouris at 1 site in France.
Trial summary
Background Managing perioperative stress, including endocrino-metabolic changes and, inflammatory and pain responses, is a major challenge to improve patient's recovery. Currently, minimally invasive surgical procedures combined with multimodal analgesia are commonly used to increase the quality of postoperative… Read more about this study
- Who is it for?
- Ages 18 to 80 years, women only
- Conditions the study is for
- Uterus Disease
- What is being tested?
- mini invasive approach and Conventional approach
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 67 participants
- Where
- 1 siteFrance
- Study dates
- 2 Dec 2019to 1 Jun 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- programmed to laparoscopic hysterectomy
- stable ASA score <3
- no contraindication to take nonsteroidal anti-inflammatory drugs
- absence of chronic pain
- perfect understanding of post-operative psycho-motor assessment
- presence of an attendant
- distance between home and hospital allowing a possible quick readmission
- acceptance to respect all the given medical instructions.
Who cannot join
- laparo-conversion and surgical or anesthetic complication.
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
Insitut Mutualiste Montsouris
Paris, 75014
M.D.,Ph.D.
Karim BOUATTOUR
About this study
Background Managing perioperative stress, including endocrino-metabolic changes and, inflammatory and pain responses, is a major challenge to improve patient's recovery. Currently, minimally invasive surgical procedures combined with multimodal analgesia are commonly used to increase the quality of postoperative period.
Purpose To demonstrate that a minimally invasive approach including low insufflation pressure and minitrocars in laparoscopic hysterectomy improves postoperative recovery and reduces pain stimulation and opioid consumption in comparison with a conventional approach.
Read more
Methods After informed consent, all patients scheduled for a laparoscopic hysterectomy including those with carcinologic disease will be part of this monocentric prospective randomized double-blinded study.
At admission in our outpatient unit, patients will have to fill the Post-operative Quality of Recovery Scale assessment form, before to be randomized into one of the following two groups:
- Conventional approach: laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
- Mini-invasive approach : laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Both groups will have general anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor) and will benefit of our enhanced recovery program. Patients and evaluators will be blind regarding the allocated group.
The primary outcome is a comparison of the postoperative recovery between the two groups through the Post-operative Quality of Recovery Scale.This evaluation will include pain data, nausea/vomiting evaluation and cognitive function 6 hours after surgery.
Secondary outcomes are morphine consumption surgical comfort and patient satisfaction.
Read the detailed description
Introduction About 43,000 hysterectomies were performed in France in 2016 half of them as a laparoscopic procedure. Compared to vaginal hysterectomy, laparoscopic surgery decreases postoperative pain and hospital length of stay [PubMed ID: 25524534 ]. Laparoscopic hysterectomy is also the most common surgical technique in the USA within enhanced recovery after surgery programs (ERAS)[2]. However, postoperative pain is still an important issue and results in most of the early re-admissions [3]. In addition, control of intraoperative stress, including painful stimuli, but also endocrine-metabolic and inflammatory responses is a major component of patient's recovery improvement. Reducing length of stay can lead to a possible outpatient surgery with a high level of quality and safety.
Hysterectomy in outpatient setting is barely done in France (0.1% in 2012 and 1.5% in 2017) compare to USA (more than 50%) so there is still a significant scope of improvement [2].
Many parameters need to be controlled to reduce perioperative stress [4,5]. Francophone teams showed that the use of mini-invasive techniques such as low and stable abdominal insufflation pressure is an important factor regarding pain and inflammation after gynecological surgery [6,7]. Furthermore to reduce parietal and peritoneal injuries can be achieved by using very small trocars while allowing surgery to be performed in good conditions [8,9]. Some teams have combined these two techniques with promising results in abdominal surgery [10].
The choice of anesthesia technic within an ERAS program that include quick elimination drugs, vascular filling monitoring and optimization, prevention of hypothermia and postoperative nausea/vomiting (PONV), as well as a multimodal analgesia, including loco-regional analgesia allow a faster postoperative recovery after pelvic surgery [11, 12]. Among these parameters, post-operative pain management is a major component. It has been demonstrated that pain prolongs surgical stress, delays mobilization and full recovery. Opioid medication therapy results in many adverse effects (PONV, sedation) and delays postoperative recovery[12]. Furthermore, availability of opioids at home is currently a real public health issue[13]. After a conventional hysterectomy use of opioids is almost systematic[14]. Therefore the challenge is to provide effective analgesia with the minimum of opioids use. Anesthesia with a deep neuromuscular blockade allows a low peritoneal pressure while maintaining optimal surgical comfort[15].
Hypothesis A mini-invasive approach of laparoscopic hysterectomy, combining mini-trocars and low pneumoperitoneum pressure would improve quality of post-operative recovery and reduce length of stay in the hospital allowing the procedure to be performed as outpatient surgery.
Purposes
- Primary goal: to demonstrate that a mini-invasive laparoscopic hysterectomy compared to a conventional approach improves the PQRS score.
- Secondary goal:
To assess intraoperative pain intensity using the Analgesia Nociception Index (ANI) and whether minimally invasive surgery reduces the use of per- and postoperative opioids, PONV and patient satisfaction.
Methods This randomized prospective study will be carried out according to CONSORT methodological standards[17].
Information and recruitment During the pre-operative clinic, surgeon will check patient's eligibility regarding the inclusion criteria and patients will receive oral and written inform consent about the study. During anesthesia clinic, eligibility for ambulatory surgery will be confirmed and informed consent will be obtained. Throughout the duration of the study (24 hours), the patient will not be able to be included in any other research protocol that could affect her post-operative recovery.
Population After informed consent, all eligible patients undergoing laparoscopic hysterectomy surgery for benign or malignant affections will be included. Inclusion criteria are: stable ASA (American Society of Anesthesiologists )score <3, no contraindication to take nonsteroidal anti-inflammatory drugs , absence of chronic pain, perfect understanding of post-operative psycho-motor assessment, presence of an attendant, distance between home and hospital allowing a possible quick readmission and acceptance to respect all the given medical instructions.
Patients will be systematically excluded in case of laparo-conversion and surgical or anesthetic complication.
Randomization and PQRS assessment:
After admission in the day surgery unit all patient included in the study will fill a PQRS form before to be randomized in one of the two groups. Randomization and intraoperative patient care will not be achieved by the PQRS assessor.
Randomization into one of the two arms will be done by using a remote computer randomization system :
- Conv group conventional approach : laparoscopic surgery using standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
- Mini-inv group mini-invasive approach: laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Both group will have an anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor).
Neither the patient nor the evaluator will be aware of the randomization group.
- The pre-operative and H6 PQRS score will be collected by an anesthesiologist not involve in patient care either per or post operatively up to 24h after surgery.
Perioperative management All patient will benefit of our ERAS protocol: fasting allowing the use of drinks up to 2 hours before anesthesia[16], general anesthesia with oro-tracheal intubation and protective mechanical ventilation (current tidal volume between 6-8 ml/kg of ideal weight and peep at 5 cmH2O) with a mixture of air and oxygen (50/50) and multimodal analgesia with intravenous lidocaine infusion (1,5 mg/kg bolus immediately after induction followed by a continuous infusion of 1,5 mg/kg/h stopped 20 min before the end of the procedure. Anesthesia will be performed according to our department protocol : induction and maintenance of anesthesia by propofol/remifentanil operated by target controlled intravenous anesthesia system (TIVA); anesthetic depth monitored with a bispectral index (BIS) between 45 and 55; per-operative analgesia provided by remifentanil with a brain concentration objective 0,35 ng/L for induction. Quality of analgesia will be monitored through the Analgesia Nociception Index (ANI). Remifentanil brain concentration objective will be changed to keep ANI in a range of 50 to 70. Depth of neuromuscular block with atracurium will be monitored by train-of-four. Neuromuscular blockade will be antagonized at the end of surgery according to the recommended procedure [17].
Routine analgesia will be started 20 minutes before the end of the procedure : paracetamol 1 g and ketoprofen up to 100 mg according to age and kidney function. Intraperitoneal (20 ml) and trocars orifices (10 ml) infiltration will be achieved by 2 mg/ml ropivacaine at the end of the procedure. In addition, heated blanket will be used to prevent hypothermia and central temperature will be monitored with esophageal temperature sensor. Dexamethasone 8 mg and droperidol 0.625 mg will be given to prevent PONV. Fluid therapy will be limited to 2 ml/kg/h besides blood loss compensation with a balanced solution of Ringer-Lactate. No urinary catheter will be placed.
In the Post-anesthesia care unit (PACU), pain at rest and cough will be assessed using a verbal numeric scale (VNS) between 0 (no pain) and 10 (worst pain imaginable). Patients will receive morphine intravenously (3 mg every 5 min) if the VNS level is >3/10. In the case of PONV, intravenous ondansetron 4 mg will be given.
Patients will be allowed to feed and intravenous catheter will be removed as soon as they leave the PACU. Patients will be invited to walk as soon as they can. Preventive anticoagulation with enoxaparin will be started 6 hours postoperatively. Postoperative analgesia will be managed by a combination of paracetamol 500 mg and opium 20 mg and ketoprofen 50 mg every 6 hours.
Patient will be discharged from the day surgery unit according to a "Chung score" > 9. Decision to keep the patient overnight will be made by the surgeon and anesthesiologist in charge of the patient regardless of the study or randomization group.
Twenty four hours after surgery, outpatient will be called at home and inpatient seen in her room by a research assistant to answer to a satisfaction survey and to assess postoperative pain intensity and by mouth morphine consumption.
Outcomes evaluation The primary outcome is a comparison between the two groups of immediate postoperative recovery as determined by the PQRS score [18], applied at the 6th postoperative hour (pain score, PONV and cognitive recovery).
The secondary outcomes are :
- intraoperative intensity of nociceptive stimulation measured by the intraoperative opioids consumption (remifentanil) according to the Analgesia Nociception Index (ANI) [19]
- postoperative pain intensity at rest, cough and walk (if possible) and based on the Verbal Numeric Scale (VNS) at H2, H6 and H24 post-operative, intravenous morphine consumption in PACU and by mouth opioids (morphine sulfate) during the first 24 post-operative hours
- Incidence of PONV
- Percentage of patients who reached the preoperative PQRS score at H6
- Surgical comfort on the Leiden scale [20]
- Surgery duration, length of stay in PACU (Aldrete score/15min)
- Number of patients with PADSS scores < 9 at H2 and H6 [21]
- Number of outpatients
- Bowel movement at H24 post-operative
- Number of patients who returned to hospital after discharge (or requiring medical contact) within 7 days after surgery.
- Patient satisfaction (EVAN score) [22]
- Potential adverse events
Statistical analysis The number of patients required to show a 5-point difference in the PQRS score, with a risk α of 5% and a risk β of 20%, taking into account a baseline score in the Conv group of 30 +/- 5 at H6 is 31 patients per group. With 20% of patients included but not evaluable or with deviations from protocol, 37 patients per group should be included. The statistical analysis will be carried out on a per-protocol basis and with intention to treat. It will be based on the t-Student test for the main criterion (PQRS) and Mann-Whitney or Chi-2 tests for other parameters depending on the type of parameter.
- Conditions
- Uterus Disease
- Being tested
- mini invasive approach, Conventional approach
- Keywords
- post operative recovery, laparoscopic hysterectomy, mini invasive surgery, low pressure laparoscopy
- Medical subject headings
- Uterine Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mini invasive approachProcedure or surgery
using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Conventional approachProcedure or surgery
laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
| Study group | Role | What they receive |
|---|---|---|
| Conventional approach | Active comparator | Conventional approach to laparoscopic hysterectomy Receives: Procedure: Conventional approach |
| Mini-invasive approach | Experimental | Mini-invasive approach to laparoscopic hysterectomy Receives: Procedure: mini invasive approach |
What is being measured
The primary outcome is the main question the study is designed to answer.
immediate postoperative recovery
determined by the Post Operative Quality of recovery scale PQRS (pain score, PONV and cognitive recovery)
Measured: 6th post-operative hour
Secondary outcomes (11)
intraoperative intensity of nociceptive stimulation
measured by the intraoperative opioids consumption (remifentanil) according to the Analgesia Nociception Index (ANI) in microgram.
Measured: 4th induction hour
postoperative pain intensity: Verbal Numeric Scale (VNS)
measured at rest, cough and walk (if possible) and based on the Verbal Numeric Scale (VNS) from 0 to 10.
Measured: 2nd, 6th and 24th post-operatives hours
Patient satisfaction: EVAN G score
EVAN G score.
Measured: 24th post-operative hour
rate of return after discharge
% of patients who returned to hospital after discharge.
Measured: Day 7 after discharge
Bowel movement
% of patients who had bowel movement in each group
Measured: Day 1 after discharge
Number of outpatients
rate of outpatients (%)
Measured: Day 1 after discharge
PADSS scores
rate of patients who had PADSS score <9.
Measured: 2nd and 6th post-operatives hours
Surgery duration, length of stay in PACU
In hh:mn
Measured: 4th post-operative hour
Surgical comfort
Leiden scale
Measured: 6th post-operative hour
intravenous morphine consumption
measured in PACU and by mouth opioids in mg.
Measured: 2nd, 6th and 24th post-operatives hours
Incidence of PONV
rate of patients with PONV
Measured: 2nd, 6th and 24th post-operatives hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Nov 2021
- Study start2 Dec 2019
- Primary completion1 Jun 2023 (estimated)
- Study completion1 Jun 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for Uterus DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 67 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Mutualiste Montsouris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Karim BOUATTOUR, Doctor, Principal investigator, Institut Mutualiste Montsouris
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05102032
- Sponsor's protocol ID
- ANEST-01-2019
- Acronym
- MIN-HYSTER
- Status last verified
- Oct 2021
- First submitted
- 3 Oct 2019
- Last updated
- 1 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Allam IS, Makled AK, Gomaa IA, El Bishry GM, Bayoumy HA, Ali DF. Total laparoscopic hysterectomy, vaginal hysterectomy and total abdominal hysterectomy using electrosurgical bipolar vessel sealing technique: a randomized controlled trial. Arch Gynecol Obstet. 2015 Jun;291(6):1341-5. doi: 10.1007/s00404-014-3571-3. Epub 2014 Dec 19.
PubMed 25524534Cohen SL, Ajao MO, Clark NV, Vitonis AF, Einarsson JI. Outpatient Hysterectomy Volume in the United States. Obstet Gynecol. 2017 Jul;130(1):130-137. doi: 10.1097/AOG.0000000000002103.
PubMed 28594764Penn CA, Morgan DM, Rice LW, Harris JA, Rauh-Hain JA, Uppal S. Timing of and Reasons for Unplanned 30-Day Readmission After Hysterectomy for Benign Disease. Obstet Gynecol. 2016 Oct;128(4):889-897. doi: 10.1097/AOG.0000000000001599.
PubMed 27607868Wijk L, Franzen K, Ljungqvist O, Nilsson K. Implementing a structured Enhanced Recovery After Surgery (ERAS) protocol reduces length of stay after abdominal hysterectomy. Acta Obstet Gynecol Scand. 2014 Aug;93(8):749-56. doi: 10.1111/aogs.12423. Epub 2014 Jun 13.
PubMed 24828471Wijk L, Franzen K, Ljungqvist O, Nilsson K. Enhanced Recovery after Surgery Protocol in Abdominal Hysterectomies for Malignant versus Benign Disease. Gynecol Obstet Invest. 2016;81(5):461-7. doi: 10.1159/000443396. Epub 2016 Jan 23.
PubMed 26799328Kyle EB, Maheux-Lacroix S, Boutin A, Laberge PY, Lemyre M. Low vs Standard Pressures in Gynecologic Laparoscopy: a Systematic Review. JSLS. 2016 Jan-Mar;20(1):e2015.00113. doi: 10.4293/JSLS.2015.00113.
PubMed 26955258Sroussi J, Elies A, Rigouzzo A, Louvet N, Mezzadri M, Fazel A, Benifla JL. Low pressure gynecological laparoscopy (7mmHg) with AirSeal(R) System versus a standard insufflation (15mmHg): A pilot study in 60 patients. J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):155-158. doi: 10.1016/j.jogoh.2016.09.003. Epub 2017 Jan 30.
PubMed 28403972Carvalho GL, Paquentin EM, Redan JA, Shadduck PP. The Science Behind Mini-Laparoscopic Cholecystectomy. Surg Technol Int. 2016 Oct 26;29:93-98.
PubMed 27466870Redan JA, Humphries AR, Farmer B, Paquentin EM, Koh CH, Chung MK, Stringel G, McCarus SD, Carvalho G, Diaz RG, Shadduck PP. "Big Operations Using Mini Instruments": The Evolution of Mini Laparoscopy in the Surgical Realm. Surg Technol Int. 2015 Nov;27:19-30.
PubMed 26680376de'Angelis N, Petrucciani N, Giannandrea G, Brunetti F. The protocol of low-impact laparoscopic cholecystectomy: the combination of mini-laparoscopy and low-pressure pneumoperitoneum. Updates Surg. 2018 Dec;70(4):553-556. doi: 10.1007/s13304-018-0591-8. Epub 2018 Aug 29.
PubMed 30159821Lee WK, Kim MS, Kang SW, Kim S, Lee JR. Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol-remifentanil total i.v. anaesthesia with desflurane anaesthesia. Br J Anaesth. 2015 Apr;114(4):663-8. doi: 10.1093/bja/aeu405. Epub 2014 Dec 10.
PubMed 25500679Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, Ljungqvist O, Soop M, Ramirez J; Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr. 2012 Dec;31(6):801-16. doi: 10.1016/j.clnu.2012.08.012. Epub 2012 Sep 26.
PubMed 23062720Bonnet F, Marret E. Postoperative pain management and outcome after surgery. Best Pract Res Clin Anaesthesiol. 2007 Mar;21(1):99-107. doi: 10.1016/j.bpa.2006.12.007.
PubMed 17489222Wong M, Morris S, Wang K, Simpson K. Managing Postoperative Pain After Minimally Invasive Gynecologic Surgery in the Era of the Opioid Epidemic. J Minim Invasive Gynecol. 2018 Nov-Dec;25(7):1165-1178. doi: 10.1016/j.jmig.2017.09.016. Epub 2017 Sep 28.
PubMed 28964926Griffith KC, Clark NV, Zuckerman AL, Ferzandi TR, Wright KN. Opioid Prescription and Patient Use After Gynecologic Procedures: A Survey of Patients and Providers. J Minim Invasive Gynecol. 2018 May-Jun;25(4):684-688. doi: 10.1016/j.jmig.2017.11.005. Epub 2017 Nov 14.
PubMed 29154933
Study at a glance
From the registry record, last updated by the sponsor on 1 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of a Minimally Invasive Approach to Laparoscopic Hysterectomy on Postoperative Recovery
- ClinicalTrials.gov ID
- NCT05102032
- Acronym / sponsor ID
- MIN-HYSTER / ANEST-01-2019
- Conditions
- Uterus Disease
- Keywords
- post operative recovery, laparoscopic hysterectomy, mini invasive surgery, low pressure laparoscopy
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 67 participants (estimated)
- Lead sponsor
- Institut Mutualiste MontsourisUniversity, hospital or other
- Study start
- 2 Dec 2019 (actual)
- Primary completion
- 1 Jun 2023 (estimated)
- Study completion
- 1 Jun 2023 (estimated)
- First posted
- 1 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background Managing perioperative stress, including endocrino-metabolic changes and, inflammatory and pain responses, is a major challenge to improve patient's recovery. Currently, minimally invasive surgical procedures combined with multimodal analgesia are commonly used to increase the quality of postoperative period.
Purpose To demonstrate that a minimally invasive approach including low insufflation pressure and minitrocars in laparoscopic hysterectomy improves postoperative recovery and reduces pain stimulation and opioid consumption in comparison with a conventional approach.
Methods After informed consent, all patients scheduled for a laparoscopic hysterectomy including those with carcinologic disease will be part of this monocentric prospective randomized double-blinded study.
At admission in our outpatient unit, patients will have to fill the Post-operative Quality of Recovery Scale assessment form, before to be randomized into one of the following two groups:
- Conventional approach: laparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
- Mini-invasive approach : laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Both groups will have general anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor) and will benefit of our enhanced recovery program. Patients and evaluators will be blind regarding the allocated group.
The primary outcome is a comparison of the postoperative recovery between the two groups through the Post-operative Quality of Recovery Scale.This evaluation will include pain data, nausea/vomiting evaluation and cognitive function 6 hours after surgery.
Secondary outcomes are morphine consumption surgical comfort and patient satisfaction.
Detailed description
Introduction About 43,000 hysterectomies were performed in France in 2016 half of them as a laparoscopic procedure. Compared to vaginal hysterectomy, laparoscopic surgery decreases postoperative pain and hospital length of stay [PubMed ID: 25524534 ]. Laparoscopic hysterectomy is also the most common surgical technique in the USA within enhanced recovery after surgery programs (ERAS)[2]. However, postoperative pain is still an important issue and results in most of the early re-admissions [3]. In addition, control of intraoperative stress, including painful stimuli, but also endocrine-metabolic and inflammatory responses is a major component of patient's recovery improvement. Reducing length of stay can lead to a possible outpatient surgery with a high level of quality and safety.
Hysterectomy in outpatient setting is barely done in France (0.1% in 2012 and 1.5% in 2017) compare to USA (more than 50%) so there is still a significant scope of improvement [2].
Many parameters need to be controlled to reduce perioperative stress [4,5]. Francophone teams showed that the use of mini-invasive techniques such as low and stable abdominal insufflation pressure is an important factor regarding pain and inflammation after gynecological surgery [6,7]. Furthermore to reduce parietal and peritoneal injuries can be achieved by using very small trocars while allowing surgery to be performed in good conditions [8,9]. Some teams have combined these two techniques with promising results in abdominal surgery [10].
The choice of anesthesia technic within an ERAS program that include quick elimination drugs, vascular filling monitoring and optimization, prevention of hypothermia and postoperative nausea/vomiting (PONV), as well as a multimodal analgesia, including loco-regional analgesia allow a faster postoperative recovery after pelvic surgery [11, 12]. Among these parameters, post-operative pain management is a major component. It has been demonstrated that pain prolongs surgical stress, delays mobilization and full recovery. Opioid medication therapy results in many adverse effects (PONV, sedation) and delays postoperative recovery[12]. Furthermore, availability of opioids at home is currently a real public health issue[13]. After a conventional hysterectomy use of opioids is almost systematic[14]. Therefore the challenge is to provide effective analgesia with the minimum of opioids use. Anesthesia with a deep neuromuscular blockade allows a low peritoneal pressure while maintaining optimal surgical comfort[15].
Hypothesis A mini-invasive approach of laparoscopic hysterectomy, combining mini-trocars and low pneumoperitoneum pressure would improve quality of post-operative recovery and reduce length of stay in the hospital allowing the procedure to be performed as outpatient surgery.
Purposes
- Primary goal: to demonstrate that a mini-invasive laparoscopic hysterectomy compared to a conventional approach improves the PQRS score.
- Secondary goal:
To assess intraoperative pain intensity using the Analgesia Nociception Index (ANI) and whether minimally invasive surgery reduces the use of per- and postoperative opioids, PONV and patient satisfaction.
Methods This randomized prospective study will be carried out according to CONSORT methodological standards[17].
Information and recruitment During the pre-operative clinic, surgeon will check patient's eligibility regarding the inclusion criteria and patients will receive oral and written inform consent about the study. During anesthesia clinic, eligibility for ambulatory surgery will be confirmed and informed consent will be obtained. Throughout the duration of the study (24 hours), the patient will not be able to be included in any other research protocol that could affect her post-operative recovery.
Population After informed consent, all eligible patients undergoing laparoscopic hysterectomy surgery for benign or malignant affections will be included. Inclusion criteria are: stable ASA (American Society of Anesthesiologists )score <3, no contraindication to take nonsteroidal anti-inflammatory drugs , absence of chronic pain, perfect understanding of post-operative psycho-motor assessment, presence of an attendant, distance between home and hospital allowing a possible quick readmission and acceptance to respect all the given medical instructions.
Patients will be systematically excluded in case of laparo-conversion and surgical or anesthetic complication.
Randomization and PQRS assessment:
After admission in the day surgery unit all patient included in the study will fill a PQRS form before to be randomized in one of the two groups. Randomization and intraoperative patient care will not be achieved by the PQRS assessor.
Randomization into one of the two arms will be done by using a remote computer randomization system :
- Conv group conventional approach : laparoscopic surgery using standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg.
- Mini-inv group mini-invasive approach: laparoscopic surgery using mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg.
Both group will have an anesthesia with a deep neuromuscular blockade (TOF = 0 at the thumb adductor).
Neither the patient nor the evaluator will be aware of the randomization group.
- The pre-operative and H6 PQRS score will be collected by an anesthesiologist not involve in patient care either per or post operatively up to 24h after surgery.
Perioperative management All patient will benefit of our ERAS protocol: fasting allowing the use of drinks up to 2 hours before anesthesia[16], general anesthesia with oro-tracheal intubation and protective mechanical ventilation (current tidal volume between 6-8 ml/kg of ideal weight and peep at 5 cmH2O) with a mixture of air and oxygen (50/50) and multimodal analgesia with intravenous lidocaine infusion (1,5 mg/kg bolus immediately after induction followed by a continuous infusion of 1,5 mg/kg/h stopped 20 min before the end of the procedure. Anesthesia will be performed according to our department protocol : induction and maintenance of anesthesia by propofol/remifentanil operated by target controlled intravenous anesthesia system (TIVA); anesthetic depth monitored with a bispectral index (BIS) between 45 and 55; per-operative analgesia provided by remifentanil with a brain concentration objective 0,35 ng/L for induction. Quality of analgesia will be monitored through the Analgesia Nociception Index (ANI). Remifentanil brain concentration objective will be changed to keep ANI in a range of 50 to 70. Depth of neuromuscular block with atracurium will be monitored by train-of-four. Neuromuscular blockade will be antagonized at the end of surgery according to the recommended procedure [17].
Routine analgesia will be started 20 minutes before the end of the procedure : paracetamol 1 g and ketoprofen up to 100 mg according to age and kidney function. Intraperitoneal (20 ml) and trocars orifices (10 ml) infiltration will be achieved by 2 mg/ml ropivacaine at the end of the procedure. In addition, heated blanket will be used to prevent hypothermia and central temperature will be monitored with esophageal temperature sensor. Dexamethasone 8 mg and droperidol 0.625 mg will be given to prevent PONV. Fluid therapy will be limited to 2 ml/kg/h besides blood loss compensation with a balanced solution of Ringer-Lactate. No urinary catheter will be placed.
In the Post-anesthesia care unit (PACU), pain at rest and cough will be assessed using a verbal numeric scale (VNS) between 0 (no pain) and 10 (worst pain imaginable). Patients will receive morphine intravenously (3 mg every 5 min) if the VNS level is >3/10. In the case of PONV, intravenous ondansetron 4 mg will be given.
Patients will be allowed to feed and intravenous catheter will be removed as soon as they leave the PACU. Patients will be invited to walk as soon as they can. Preventive anticoagulation with enoxaparin will be started 6 hours postoperatively. Postoperative analgesia will be managed by a combination of paracetamol 500 mg and opium 20 mg and ketoprofen 50 mg every 6 hours.
Patient will be discharged from the day surgery unit according to a "Chung score" > 9. Decision to keep the patient overnight will be made by the surgeon and anesthesiologist in charge of the patient regardless of the study or randomization group.
Twenty four hours after surgery, outpatient will be called at home and inpatient seen in her room by a research assistant to answer to a satisfaction survey and to assess postoperative pain intensity and by mouth morphine consumption.
Outcomes evaluation The primary outcome is a comparison between the two groups of immediate postoperative recovery as determined by the PQRS score [18], applied at the 6th postoperative hour (pain score, PONV and cognitive recovery).
The secondary outcomes are :
- intraoperative intensity of nociceptive stimulation measured by the intraoperative opioids consumption (remifentanil) according to the Analgesia Nociception Index (ANI) [19]
- postoperative pain intensity at rest, cough and walk (if possible) and based on the Verbal Numeric Scale (VNS) at H2, H6 and H24 post-operative, intravenous morphine consumption in PACU and by mouth opioids (morphine sulfate) during the first 24 post-operative hours
- Incidence of PONV
- Percentage of patients who reached the preoperative PQRS score at H6
- Surgical comfort on the Leiden scale [20]
- Surgery duration, length of stay in PACU (Aldrete score/15min)
- Number of patients with PADSS scores < 9 at H2 and H6 [21]
- Number of outpatients
- Bowel movement at H24 post-operative
- Number of patients who returned to hospital after discharge (or requiring medical contact) within 7 days after surgery.
- Patient satisfaction (EVAN score) [22]
- Potential adverse events
Statistical analysis The number of patients required to show a 5-point difference in the PQRS score, with a risk α of 5% and a risk β of 20%, taking into account a baseline score in the Conv group of 30 +/- 5 at H6 is 31 patients per group. With 20% of patients included but not evaluable or with deviations from protocol, 37 patients per group should be included. The statistical analysis will be carried out on a per-protocol basis and with intention to treat. It will be based on the t-Student test for the main criterion (PQRS) and Mann-Whitney or Chi-2 tests for other parameters depending on the type of parameter.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Conventional approach | Active comparator | Procedure: Conventional approachConventional approach to laparoscopic hysterectomy |
| Mini-invasive approach | Experimental | Procedure: mini invasive approachMini-invasive approach to laparoscopic hysterectomy |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- programmed to laparoscopic hysterectomy
- stable ASA score <3
- no contraindication to take nonsteroidal anti-inflammatory drugs
- absence of chronic pain
- perfect understanding of post-operative psycho-motor assessment
Key exclusion criteria (1 listed)
- laparo-conversion and surgical or anesthetic complication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mini invasive approachusing mini-trocars (3 trocars of 3 mm and a 5 mm-optic trocar) with insufflation pressures of less than 8 mmHg. | Procedure or surgery | Mini-invasive approach |
| Conventional approachlaparoscopic procedure including standard trocars (3 trocars of 5 mm and a 10 mm-optic trocar) with insufflation pressures between 10 and 12 mmHg. | Procedure or surgery | Conventional approach |
Primary outcome
immediate postoperative recovery
Time frame: 6th post-operative hour
determined by the Post Operative Quality of recovery scale PQRS (pain score, PONV and cognitive recovery)
11 secondary outcomes
intraoperative intensity of nociceptive stimulation
Time frame: 4th induction hour
postoperative pain intensity: Verbal Numeric Scale (VNS)
Time frame: 2nd, 6th and 24th post-operatives hours
Patient satisfaction: EVAN G score
Time frame: 24th post-operative hour
rate of return after discharge
Time frame: Day 7 after discharge
Bowel movement
Time frame: Day 1 after discharge
Number of outpatients
Time frame: Day 1 after discharge
PADSS scores
Time frame: 2nd and 6th post-operatives hours
Surgery duration, length of stay in PACU
Time frame: 4th post-operative hour
Surgical comfort
Time frame: 6th post-operative hour
intravenous morphine consumption
Time frame: 2nd, 6th and 24th post-operatives hours
Incidence of PONV
Time frame: 2nd, 6th and 24th post-operatives hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Nov 2021.
- Background: PubMed 25524534Allam IS, Makled AK, Gomaa IA, El Bishry GM, Bayoumy HA, Ali DF. Total laparoscopic hysterectomy, vaginal hysterectomy and total abdominal hysterectomy using electrosurgical bipolar vessel sealing technique: a randomized controlled trial. Arch Gynecol Obstet. 2015 Jun;291(6):1341-5. doi: 10.1007/s00404-014-3571-3. Epub 2014 Dec 19.
- Background: PubMed 28594764Cohen SL, Ajao MO, Clark NV, Vitonis AF, Einarsson JI. Outpatient Hysterectomy Volume in the United States. Obstet Gynecol. 2017 Jul;130(1):130-137. doi: 10.1097/AOG.0000000000002103.
- Background: PubMed 27607868Penn CA, Morgan DM, Rice LW, Harris JA, Rauh-Hain JA, Uppal S. Timing of and Reasons for Unplanned 30-Day Readmission After Hysterectomy for Benign Disease. Obstet Gynecol. 2016 Oct;128(4):889-897. doi: 10.1097/AOG.0000000000001599.
- Background: PubMed 24828471Wijk L, Franzen K, Ljungqvist O, Nilsson K. Implementing a structured Enhanced Recovery After Surgery (ERAS) protocol reduces length of stay after abdominal hysterectomy. Acta Obstet Gynecol Scand. 2014 Aug;93(8):749-56. doi: 10.1111/aogs.12423. Epub 2014 Jun 13.
- Background: PubMed 26799328Wijk L, Franzen K, Ljungqvist O, Nilsson K. Enhanced Recovery after Surgery Protocol in Abdominal Hysterectomies for Malignant versus Benign Disease. Gynecol Obstet Invest. 2016;81(5):461-7. doi: 10.1159/000443396. Epub 2016 Jan 23.
- Background: PubMed 26955258Kyle EB, Maheux-Lacroix S, Boutin A, Laberge PY, Lemyre M. Low vs Standard Pressures in Gynecologic Laparoscopy: a Systematic Review. JSLS. 2016 Jan-Mar;20(1):e2015.00113. doi: 10.4293/JSLS.2015.00113.
- Background: PubMed 28403972Sroussi J, Elies A, Rigouzzo A, Louvet N, Mezzadri M, Fazel A, Benifla JL. Low pressure gynecological laparoscopy (7mmHg) with AirSeal(R) System versus a standard insufflation (15mmHg): A pilot study in 60 patients. J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):155-158. doi: 10.1016/j.jogoh.2016.09.003. Epub 2017 Jan 30.
- Background: PubMed 27466870Carvalho GL, Paquentin EM, Redan JA, Shadduck PP. The Science Behind Mini-Laparoscopic Cholecystectomy. Surg Technol Int. 2016 Oct 26;29:93-98.
- Background: PubMed 26680376Redan JA, Humphries AR, Farmer B, Paquentin EM, Koh CH, Chung MK, Stringel G, McCarus SD, Carvalho G, Diaz RG, Shadduck PP. "Big Operations Using Mini Instruments": The Evolution of Mini Laparoscopy in the Surgical Realm. Surg Technol Int. 2015 Nov;27:19-30.
- Background: PubMed 30159821de'Angelis N, Petrucciani N, Giannandrea G, Brunetti F. The protocol of low-impact laparoscopic cholecystectomy: the combination of mini-laparoscopy and low-pressure pneumoperitoneum. Updates Surg. 2018 Dec;70(4):553-556. doi: 10.1007/s13304-018-0591-8. Epub 2018 Aug 29.
- Background: PubMed 25500679Lee WK, Kim MS, Kang SW, Kim S, Lee JR. Type of anaesthesia and patient quality of recovery: a randomized trial comparing propofol-remifentanil total i.v. anaesthesia with desflurane anaesthesia. Br J Anaesth. 2015 Apr;114(4):663-8. doi: 10.1093/bja/aeu405. Epub 2014 Dec 10.
- Background: PubMed 23062720Nygren J, Thacker J, Carli F, Fearon KC, Norderval S, Lobo DN, Ljungqvist O, Soop M, Ramirez J; Enhanced Recovery After Surgery Society. Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations. Clin Nutr. 2012 Dec;31(6):801-16. doi: 10.1016/j.clnu.2012.08.012. Epub 2012 Sep 26.
Related trials for Uterus Disease
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Not yet recruiting
Comparison of Effect of Two Different Doses of Intravenous Oxytocin on Patients Undergoing Elective Cesarean Section
Postpartum Hemorrhage, Uterine Atony
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Active, not recruitingPhase 3
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Endometrial Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Karim BOUATTOUR, Doctor principal investigator
Institut Mutualiste Montsouris
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing mini invasive approach and Conventional approach in people with Uterus Disease, run by Institut Mutualiste Montsouris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Responsable of Clinical Research Unit (+ 33 156616705, isabelle.sauret@imm.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
immediate postoperative recovery (time frame: 6th post-operative hour). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05102032, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Nov 2021.